2016 年業績 · 2017. 5. 29. · Comparison of PD-L1 expression between tumor tissues and...
12
- 1 - 2016 年業績 【原著】 1. Tanaka A, Akamatsu H, Kawabata H, Ariyasu H, Nakamura Y, Yamamoto N: Peripheral pulmonary carcinoid tumor diagnosed by endobronchial ultrasound guided bronchoscopy. Respirol Case Rep 4(1): 10-12, 2016 2. Chu D, Paoletti C, Gersch C, VanDenBerg D, Zabransky D, Cochran R, Wong HY, Valda Toro P, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons H, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan A, Schott AF, Robinson DR, Jacks K, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH: ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin Cancer Res 22(4): 993-999, 2016 3. Imai H, Murakami H, Yoshino R, Mori K, Sumita K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Harada H, Naito T, Kaira K, Tomizawa Y, Ohde Y, Matsuura M, Endo M, Saito R, Nakajima T, Takahashi T: Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage Ⅲ disease in non-small cell lung cancer patients. J BUON 21(2): 333-340, 2016 4. Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K: Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget 7(36): 58492-58499, 2016 5. Hayata A, Minakata Y, Matsunaga K, Nakanishi M, Yamamoto N: Differences in physical activity according to mMRC grade in patients with COPD. Int J Chron Obstruct Pulmon Dis 11: 2203-2208, 2016 6. Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF: Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Mol Oncol 10(7):1078-1085, 2016 7. Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T, Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y, Koizumi F: A sensitive cytometry based system for enumeration, capture and
2016 年業績 · 2017. 5. 29. · Comparison of PD-L1 expression between tumor tissues and circulating tumor cells and tumor tissues in patients with lung cancer. EORTC-NCI-AACR
2016
1. Tanaka A, Akamatsu H, Kawabata H, Ariyasu H, Nakamura Y,
Yamamoto N: Peripheral pulmonary carcinoid tumor diagnosed by
endobronchial ultrasound guided bronchoscopy. Respirol Case Rep
4(1): 10-12, 2016
2. Chu D, Paoletti C, Gersch C, VanDenBerg D, Zabransky D, Cochran
R, Wong HY, Valda Toro P, Cidado J, Croessmann S, Erlanger B,
Cravero K, Kyker-Snowman K, Button B, Parsons H, Dalton WB, Gillani
R, Medford A, Aung K, Tokudome N, Chinnaiyan A, Schott AF, Robinson
DR, Jacks K, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH: ESR1
mutations in circulating plasma tumor DNA from metastatic breast
cancer patients. Clin Cancer Res 22(4): 993-999, 2016
3. Imai H, Murakami H, Yoshino R, Mori K, Sumita K, Ono A, Akamatsu
H, Taira T, Kenmotsu H, Harada H, Naito T, Kaira K, Tomizawa Y,
Ohde Y, Matsuura M, Endo M, Saito R, Nakajima T, Takahashi T:
Comparison of the efficacy of radiotherapy between postoperative
mediastinal lymph node recurrence and stage disease in non-small
cell lung cancer patients. J BUON 21(2): 333-340, 2016
4. Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M,
Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu
H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa
K, Nishio K: Detection of the T790M mutation of EGFR in plasma of
advanced non-small cell lung cancer patients with acquired
resistance to tyrosine kinase inhibitors (West Japan oncology group
8014LTR study). Oncotarget 7(36): 58492-58499, 2016
5. Hayata A, Minakata Y, Matsunaga K, Nakanishi M, Yamamoto N:
Differences in physical activity according to mMRC grade in
patients with COPD. Int J Chron Obstruct Pulmon Dis 11: 2203-2208,
2016
6. Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP,
Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese
DA, Schott AF, Henry NL, Rae JM, Hayes DF: Heterogeneous estrogen
receptor expression in circulating tumor cells suggests diverse
mechanisms of fulvestrant resistance. Mol Oncol 10(7):1078-1085,
2016
7. Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T,
Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y,
Koizumi F: A sensitive cytometry based system for enumeration,
capture and
- 2 -
analysis of gene mutations of circulating tumor cells. Cancer Sci
107(3): 307-314, 2016
8. Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, Tagawa T,
Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y,
Serizawa M, Tamiya A, Shimizu S, Yoshimoto N, Kubo A, Isa S, Saka
H, Matsumura A: Prospective analysis on oncogenic driver mutations
and environmental factors: Japan Molecular Epidemiology for lung
cancer study (JME). J Clin Oncol 34(19): 2247-2257, 2016
9. Kikuchi T, Akamatsu H, Mori K, Tanaka A, Kanai K, Hayata A,
Tokudome N, Akamatsu K, Koh Y, Nakanishi M, Ueda H, Yamamoto N:
Applicability of the Japanese equation for estimating glomerular
filtration rate in patients with advanced-stage thoracic cancer.
Respir Investig 54(6): 479-483, 2016
10. Ono A, Murakami H, Serizawa M, Wakuda K, Kenmotsu H, Naito T,
Taira T, Koh Y, Ohde Y, Nakajima T, Endo M, Takahashi T: Drastic
initial response and subsequent response to two ALK inhibitors in a
patient with a highly aggressive ALK-rearranged inflammatory
myofibroblastic tumor arising in the pleural cavity. Lung Cancer
99: 151-154, 2016
11. Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, Taira T,
Naito T, Murakami H, Isaka M, Endo M, Nakajima T, Ohde Y, Yamamoto
N, Takahashi K, Takahashi T: Frequency of EGFR T790M mutation and
multimutational profiles of rebiopsy samples from non-small cell
lung cancer developing acquired resistance to EGFR tyrosine kinase
inhibitors in Japanese patients. BMC Cancer 16(1): 864, 2016
12. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I,
Nakagawa K, Yamamoto N, Muto S, Fukuoka M: Characteristics and
overall survival of EGFR mutation-positive non-small cell lung
cancer treated with EGFR tyrosine kinase inhibitors: a
retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol
46(5): 462-467, 2016
13. Schuler M, Wu YL, Hirsh V, O’Byrne K, Yamamoto N, Mok T, Popat
S, Sequist LV, Massey D, Zazulina V, Yang JC: First-Line Afatinib
versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and
Common Epidermal Growth Factor Receptor Gene Mutations and Brain
Metastases. J Thorac Oncol 11(3): 380-390 2016
14. Sekine I, Sumi M, Satouchi M, Tsujino K, Nishio M, Kozuka T,
Niho S, Nihei K, Yamamoto N, Harada H, Ishikura S, Tamura T:
Feasibility study
of chemoradiotherapy followed by amrubicin and cisplatin for
limited-disease small cell lung cancer. Cancer Sci 107(3): 315-319,
2016
15. Ryuge S, Masuda N, Yamamoto N, Takahashi T, Murakami H, Takeda
H, Daga H, Yonesaka K, Tsukuda H, Nakagawa K, Tanaka K, Kiura K,
Takigawa N, Hida T, Seto T, Yokoba M, Kudoh S, Takagaki T, Shono K,
Kitagawa H, Kurihara T, Fukuoka M: Phramacokinetics of amrubicin in
cancer patients with inpaired hepatic function. Cancer Treatment
and Research Communications 9: 81-87, 2016
16. Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T,
Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H,
Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K: Phase II
study of erlotinib plus tivantinib (ARQ 197) in patients with
locally advanced or metastatic EGFR mutation-positive
non-small-cell lung cancer just after progression on EGFR-TKI,
gefitinib or erlotinib. ESMO Open 1(4): e000063, 2016
17. Nosaki K, Satouch M, Kurata T, Yoshida T, Okamoto I, Katakami
N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka
H, Yoshioka H, Watanabe K, Mizuno K, Seto T: Re-biopsy status among
non-small cell lung cancer patients in Japan: A retrospective
study. Lung Cancer 101: 1-8, 2016
18. Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A,
Fukuoka M: Bevacizumab for nonsmallcell lung cancer: A nested case
control study of risk factors for hemoptysis. Cancer Sci 107(12):
1837-1842, 2016
19. Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N,
Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D,
Tamura T, Nakagawa K: A randomized, double-blind, phase II study of
ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese
patients with stage IV non-small cell lung cancer after disease
progression on platinum-based therapy. Lung Cancer 99: 186-193,
2016
20. Atagi S, Goto K, Seto T, Yamamoto N, Tamura T, Tajima K,
Inagaki N: Erlotinib for Japanese patients with activating EGFR
mutation-positive non-small-cell lung cancer: combined analyses
from two Phase II studies. Future Oncol 12(18): 2117-2126,
2016
21. , , , , , , , : (ROSE). 38(6): 490-493, 2016
- 4 -
22. , , , , , , : EGFR -
-. 32(12): 941-949, 2016 23. , , , , , , ,
:
1. Koh Y, Yamamoto N: Circulating tumor cells (CTCs) in the era of
precision
cancer medicine: the potential of CTCs as a predictive biomarker
for anti-PD-1 therapeutics in patients with advanced lung cancer.
Japan-US Workshop for Cancer Research. 2016.3.7-8, Tokyo,
Japan
2. Koh Y, Yagi S, Akamatsu H, Tanaka A, Kanai K, Hayata A, Tokudome
N, Akamatsu K, Higuchi M, Kanbara H, Ueda H, Nakanishi M, Yamamoto
N: Comparison of PD-L1 expression between tumor tissues and
circulating tumor cells and tumor tissues in patients with lung
cancer. EORTC-NCI-AACR 2016, 2016.11.29-12.2, Munich, Germany
1. Koh Y, Kawaguchi T, Watanabe M, Isa S, Ando M, Tamiya A, Kubo A,
Saka
H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K,
Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A: Ultra-sensitive
picodroplet digital PCR assay for multiplex genotyping of mutations
in epidermal growth factor receptor (EGFR) in non-small cell lung
cancer patients. American Association for Cancer Research Annual
Meeting 2016,
- 6 -
2016.4.16-20, New Orleans, Louisiana, USA
2. Akamatsu H, Koh Y, Morita S, Yamamoto N, Nakagawa K. A
prospective biomarker study using digital PCR method in EGFR
mutated, advanced lung adenocarcinoma patients treated with
afatinib. American Association for Cancer Research Annual Meeting
2016, 2016.4.16-20, New Orleans, Louisiana, USA
3. Kim W, Koh Y, Akamatsu H, Yagi S, Tanaka A, Kanai K, Hayata A,
Shibaki R, Higuchi M, Kanbara H, Kikuchi T, Akamatsu K, Nakanishi
M, Ueda H, Yamamoto N: Differential expression of PD-L1 on
circulating tumor cells in patients with advanced lung cancer.
American Association for Cancer Research Annual Meeting 2016,
2016.4.16-20, New Orleans, Louisiana, USA
4. Yagi S, Koh Y, Akamatsu H, Kim W, Tanaka A, Kanai K, Hayata A,
Shibaki R, Higuchi M, Kanbara H, Kikuchi T, Akamatsu K, Nakanishi
M, Ueda H, Yamamoto N: Development of an automated device for
size-based enrichment and isolation of circulating tumor cells in
lung cancer patients. American Association for Cancer Research
Annual Meeting 2016, 2016.4.16-20, New Orleans, Louisiana,
USA
5. Kasahara N, Kenmotsu H, Serizawa M, Umehara R, Wakuda K, Omori
S, Nakashima K, Ono A, Taira T, Naito T, Murakami H, Sunaga N, Koh
Y, Mori K, Endo M, Nakajima T, Yamada M, Kusuhara M, Takahashi T:
Plasma epidermal growth factor receptor mutation (EGFR) testing in
advanced non-small-cell lung cancer patients harboring EGFR
mutations by chip-based digital PCR system. American Association
for Cancer Research Annual Meeting 2016, 2016.4.16-20, New Orleans,
Louisiana, USA
6. Kawaguchi T, Koh Y, Ando M, Isa S, Tamiya A, Kubo A, Yoshimoto
N, Kitagawa C, Saka H, Hirata H, Matsumura A: Mutational landscape
of non-small cell lung cancer (NSCLC) associated with chronic
obstructive pulmonary disease (COPD). American Society for Clinical
Oncology Annual Meeting 2016, 2016.6.2-6, Chicago, Illinoi,
USA
7. Koh Y, Yagi S, Akamatsu H, Tanaka A, Kanai K, Hayata A, Tokudome
N, Akamatsu K, Higuchi M, Kanbara H, Ueda H, Nakanishi M, Yamamoto
N: Comparative analysis of PD-L1 expression between circulating
tumor cells and tumor tissues in patients with lung cancer. IASLC
17th World Conference on Lung Cancer 2016, 2016.12.4-7, Vienna,
Austria
- 7 -
8. Akamatsu H, Koh Y, Morita S, Fujimoto D, Okamoto I, Bessho A,
Azuma K, Nakagawa K, Yamamoto N: A phase II, liquid biopsy study
using digital PCR in EGFR mutated, lung cancer patients treated
with afatinib (WJOG 8114LTR). IASLC 17th World Conference on Lung
Cancer 2016, 2016.12.4-7, Vienna, Austria
9. Hayakawa K, Nishimura Y, Harada H, Soejima T, Tsujino K, Kozuka
T, Tanaka M, Sasaki T, Yamamoto N, Nakagawa K: Phase II study of
nimotuzumab + conrurrent chemoradiotherapy (CRT) for stage III
non-small cell lung cancer (NSCLC): 5-year follow up results. IASLC
17th World Conference on Lung Cancer 2016, 2016.12.4-7, Vienna,
Austria
10. Kim Y, Hida T, Nokihara H, Kondo M, Azuma K, Seto T, Takigucgi
Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K,
Nakagawa K, Mitsudomi T, Yamamoto N, Kuriki H, Asabe R, Tanaka T,
Tamura T: Alectinib (ALC) versus Crizotinib (CRZ) in ALk-positive
non-small cell lung cancer (ALK+ NSCLC): Primary results form phase
III study (J-ALEX). IASLC 17th World Conference on Lung Cancer
2016, 2016.12.4-7, Vienna, Austria
11. Azuma K, Takahama T, Sakai K, Takeda M, Hida T, Hirabayashi M,
Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu
H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Yamamoto N, Nakanishi
Y, Nakagawa K, Nihio K: Detection of the T790M mutation fo EGFR in
plasma of advanced NSCLC patients with acquired resistance to
EGFR-TKI (WJOG8014LTR). IASLC 17th World Conference on Lung Cancer
2016, 2016.12.4-7, Vienna, Austria
12. Yoshida K, Ohe Y, Inoue A, Kumagai T, Takeda M, Yamamoto N,
Seto T, Okamoto I, Tashiro N, Morita S, Fukuoka M: Overall survival
(OS) of EGFR mutation positive non-small cell lung cancer patients:
real-world treatment patterns of 1,660 Japanese patients. IASLC
17th World Conference on Lung Cancer 2016, 2016.12.4-7, Vienna,
Austria
13. Niwa T, Yoshioka H, Hata A, Azuma K, Tajima M, Morita M, Kogure
Y, Akamatsu H, Ishida T, Katakami N, Hoshino T, Takenoyama M,
Takahashi K, Kaneda H, Tomioka H, Saka H, Ando M, Yamamoto N: The
NICE slavage study: a phase II trial of weekly nab-paclitaxel in
the salvage setting for advanced non-small cell lung cancer. IASLC
17th World Conference on Lung Cancer 2016, 2016.12.4-7, Vienna,
Austria
14. Mok T, Schmid P, De Castro G Jr, Syrigos K, Martin C, Yamamoto
N, Arn
- 8 -
O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva, Trani L:
First-line durvalmab plus tremelimumab vs platinum-based
chemotherapy for advanced/metastatic NSCLC: phase 3 NEPTUNE study.
IASLC 17th World Conference on Lung Cancer 2016, 2016.12.4-7,
Vienna, Austria
15. Kanda S, Mizutani T, Shibata T, Niho S, Kurata T, Nakamura S,
Yamamoto N, Ohe Y: A phase III study comparing gefitinib and
inserted cisplatin plus pemetrexed with gefitinib for EGFR-mutated
advanced non-squamous NSCLC. IASLC 17th World Conference on Lung
Cancer 2016, 2016.12.4-7, Vienna, Austria
16. Yokomise H, Tanaka F, Soejima T, Uramoto H, Yamanaka T,
Yamamoto N, Nakagawa K, Nishimura Y, Niwa H, Okada M, Nakagawa T,
Yamashita M: A feasibility study of concurrent chemoradiation
followed by surgery for pathologically-proven clinical IIIA-N2
non-small cell lung cancer. NSCLC. IASLC 17th World Conference on
Lung Cancer 2016, 2016.12.4-7, Vienna, Austria
, , 2016.3.11 2. : . 56 (
), , 2016.4.8-10 3. : . 56
(), , 2016.4.8-10 4. : . 66 , ,
2016.9.3 5. : EGFR-TKI . 57
(), , 2016.12.19-21 6. , , , , , , , ,
, , , , , , ,
, , : ALK (ALC) (CRZ) III(j-ALEX). 57
(), , 2016.12.19-21 7. : WJOG .
. 57 , , 2016.12.19-21 8. , , , : IPF
- 9 -
carboplatin + nab-paclitaxel +/- nintedanib II . 57 , ,
2016.12.19-21
1. Tanaka A, Koh Y, Kim W, Akamatsu H, Yagi S, Kanai K, Higuchi
M,
Kanbara H, Kikuchi T, Yamamoto N: Evaluation of a novel automated
device for size-based enrichment and isolation of CTCs in patients
with advanced lung cancer. 56 , , 2016.4.8-10
2. , , , , , , , , , , , , , , , : EGFR-TKI
. 56 , , 2016.4.8-10 3. : 2 .
113 , , 2016.4.15-17 4. , , :
. 115 , , 2016.6.3-5 5. , Hyeun Joong Yoon, Tomas Bersano, Dafydd
Thomas, Costanza
Paoletti, Kimberly Michael, Martha Brown, James M Rae, Sunitha
Nagrath, Daniel F Hayes. (CTC)
EpCAM . 24 , , 2016.6.16-18
6. Yamamoto N: Impact of dose adjustment on the safety and efficacy
of afatinib in patients with advanced EGFR mutation -positive
NSCLC. 14 , , 2016.7.28-30
7. : . 14 , , 2016.7.28-30
8. , , , , , , , , , :
1 . 14
, , 2016.7.28-30 9. : PD-L1 . 14
, , 2016.7.28-30 10. Yagi S, Koh Y, Akamatsu H, Kanai K, Hayata A,
Akamatsu K, Higuchi M,
Kanbara H, Nakanishi M, Ueda H, Yamamoto N: Development of the
automated size-based filtration system for isolation of CTCs in
lung cancer
patients. 14 , , 2016.7.28-30 11. Tokudome N, Ueda H, Nakanishi M,
Hayata A, Akamatsu H, Tanaka A,
Koh Y, Kikuchi T, Akamatsu K, Yamamoto N: Detection and management
of everolimus associated pneumonitis with serum markers for
interstitial pneumonia. 14 , , 2016.7.28-30
12. Koh Y, Akamatsu H, Yagi S, Tanaka A, Kanai K, Hayata A,
Tokudome N, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N:
Diverse patterns of PD-L1 expression on circulating tumor cells in
Japanese patients with advanced lung cancer. 75 , ,
2016.10.6-8
13. Kubo A, Kawaguchi T, Watanabe M, Isa S, Ando M, Tamiya A, Saka
H, Takeo S, Adachi H, Tagawa T, Matsumura A, Koh Y: Ultra-sensitive
picodroplet digital PCR assay for multiplex genotyping of EGFR
mutations in non-small cell lung cancer. 75 , , 2016.10.6-8
14. Yagi S, Koh Y, Akamatsu H, Tanaka A, Kanai K, Hayata A,
Akamatsu K, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N:
Development of the automated size-based filtration system for
isolation of CTCs in lung cancer patients. 75 , , 2016.10.6-8
15. Yamamoto N: Treatment guideline in Japan. 54
, , 2016.10.20-22 16. :
. 54
, , 2016.10.20-22 17. :
1 . 55 , , 2016.11.18-19 18. , , , , , , ,
, , , , , , :
. 57
, , 2016.12.19-21 19. , , , , , , , ,
, , : A real world evidence of 1,660 Japanese patients with NSCLC
harboring EGFR mutation. 57
, , 2016.12.19-21 20. , , , , , , ,
, , , , :
- 11 -
S-1 + CDDP + (SR+TRT)
. 57 , , 2016.12.19-21 21. , , , , : DNA
T790M EGFRTKI
II . 57 , , 2016.12.19-21 22. , , , , , ,
, , , , , , ,
: . 57 , , 2016.12.19-21
23. , , , , , ,
, , , , , , ,
, , :
2 1 . 57
, , 2016.12.19-21 24. , , , , , , ,
, , , , , , : PD-L1 . 57
, , 2016.12.19-21 25. , , , , , , ,
, , , , , :
CTC . 57 ,
, 2016.12.19-21
109 (), , 2016.5.22
1. , , , , , , ,
, :
. 84 , , 2016.7.3 2. , , , , , ,
, , , , , , ,
, , : 2 . 104
, , 2016.7.16
3. : . 55
, , 2016.10.23 4. , , , , , , ,
, , :
5. , , , , , ,
, , , , , , ,
: . 88,
2016
1. Tanaka A, Akamatsu H, Kawabata H, Ariyasu H, Nakamura Y,
Yamamoto N: Peripheral pulmonary carcinoid tumor diagnosed by
endobronchial ultrasound guided bronchoscopy. Respirol Case Rep
4(1): 10-12, 2016
2. Chu D, Paoletti C, Gersch C, VanDenBerg D, Zabransky D, Cochran
R, Wong HY, Valda Toro P, Cidado J, Croessmann S, Erlanger B,
Cravero K, Kyker-Snowman K, Button B, Parsons H, Dalton WB, Gillani
R, Medford A, Aung K, Tokudome N, Chinnaiyan A, Schott...
3. Imai H, Murakami H, Yoshino R, Mori K, Sumita K, Ono A, Akamatsu
H, Taira T, Kenmotsu H, Harada H, Naito T, Kaira K, Tomizawa Y,
Ohde Y, Matsuura M, Endo M, Saito R, Nakajima T, Takahashi T:
Comparison of the efficacy of radiotherapy between postop...
4. Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M,
Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu
H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa
K, Nishio K: Detection of the T790M mutation of EGFR...
5. Hayata A, Minakata Y, Matsunaga K, Nakanishi M, Yamamoto N:
Differences in physical activity according to mMRC grade in
patients with COPD. Int J Chron Obstruct Pulmon Dis 11: 2203-2208,
2016
6. Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP,
Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese
DA, Schott AF, Henry NL, Rae JM, Hayes DF: Heterogeneous estrogen
receptor expression in circulating tumor cells sugge...
7. Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T,
Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y,
Koizumi F: A sensitive cytometry based system for enumeration,
capture and analysis of gene mutations of circulating tumo...
8. Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, Tagawa T,
Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y,
Serizawa M, Tamiya A, Shimizu S, Yoshimoto N, Kubo A, Isa S, Saka
H, Matsumura A: Prospective analysis on oncogenic driver ...
9. Kikuchi T, Akamatsu H, Mori K, Tanaka A, Kanai K, Hayata A,
Tokudome N, Akamatsu K, Koh Y, Nakanishi M, Ueda H, Yamamoto N:
Applicability of the Japanese equation for estimating glomerular
filtration rate in patients with advanced-stage thoracic
ca...
10. Ono A, Murakami H, Serizawa M, Wakuda K, Kenmotsu H, Naito T,
Taira T, Koh Y, Ohde Y, Nakajima T, Endo M, Takahashi T: Drastic
initial response and subsequent response to two ALK inhibitors in a
patient with a highly aggressive ALK-rearranged infl...
11. Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, Taira T,
Naito T, Murakami H, Isaka M, Endo M, Nakajima T, Ohde Y, Yamamoto
N, Takahashi K, Takahashi T: Frequency of EGFR T790M mutation and
multimutational profiles of rebiopsy samples from n...
12. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I,
Nakagawa K, Yamamoto N, Muto S, Fukuoka M: Characteristics and
overall survival of EGFR mutation-positive non-small cell lung
cancer treated with EGFR tyrosine kinase inhibitors: a
retros...
13. Schuler M, Wu YL, Hirsh V, O’Byrne K, Yamamoto N, Mok T, Popat
S, Sequist LV, Massey D, Zazulina V, Yang JC: First-Line Afatinib
versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and
Common Epidermal Growth Factor Receptor Gene Mutat...
14. Sekine I, Sumi M, Satouchi M, Tsujino K, Nishio M, Kozuka T,
Niho S, Nihei K, Yamamoto N, Harada H, Ishikura S, Tamura T:
Feasibility study of chemoradiotherapy followed by amrubicin and
cisplatin for limited-disease small cell lung cancer.
Cancer...
15. Ryuge S, Masuda N, Yamamoto N, Takahashi T, Murakami H, Takeda
H, Daga H, Yonesaka K, Tsukuda H, Nakagawa K, Tanaka K, Kiura K,
Takigawa N, Hida T, Seto T, Yokoba M, Kudoh S, Takagaki T, Shono K,
Kitagawa H, Kurihara T, Fukuoka M: Phramacokinetic...
16. Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T,
Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H,
Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K: Phase II
study of erlotinib plus tivantinib (ARQ 197) in patients
wi...
17. Nosaki K, Satouch M, Kurata T, Yoshida T, Okamoto I, Katakami
N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka
H, Yoshioka H, Watanabe K, Mizuno K, Seto T: Re-biopsy status among
non-small cell lung cancer patients in Japan: A r...
18. Goto K,P PEndo M,P PKusumoto M,P PYamamoto N,P POhe Y,P
PShimizu A,P PFukuoka M: Bevacizumab for nonsmallcell lung cancer:
A nested case control study of risk factors for hemoptysis. Cancer
Sci 107(12): 1837-1842, 2016
19. Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N,
Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D,
Tamura T, Nakagawa K: A randomized, double-blind, phase II study of
ramucirumab plus docetaxel vs placebo plus docetaxel...
20. Atagi S, Goto K, Seto T, Yamamoto N, Tamura T, Tajima K,
Inagaki N: Erlotinib for Japanese patients with activating EGFR
mutation-positive non-small-cell lung cancer: combined analyses
from two Phase II studies. Future Oncol 12(18): ...
21. , , , , , , , : (ROSE). 38(6): 490-493, 2016
22. , , , , , , : EGFR--. 32(12): 941-949, 2016
